Qube Research & Technologies (QRT)
DYN icon

Qube Research & Technologies (QRT)’s Dyne Therapeutics DYN Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.52M Buy
+218,805
New +$5.03M ﹤0.01% 2007
2026
Q2 		– Sell
-253,153
Closed -$4.59M – 3612
2026
Q1 		$4.59M Sell
253,153
-159,287
-39% -$2.75M 0.01% 1706
2025
Q4 		$8.07M Sell
412,440
-417,329
-50% -$7.9M 0.01% 1480
2025
Q3 		$10.5M Buy
829,769
+37,782
+5% +$431K 0.01% 1295
2025
Q2 		$7.54M Buy
791,987
+111,151
+16% +$1.22M 0.01% 1466
2025
Q1 		$7.12M Buy
680,836
+413,459
+155% +$5.91M 0.01% 1339
2024
Q4 		$6.3M Buy
267,377
+244,211
+1,054% +$7.22M 0.01% 1362
2024
Q3 		$832K Buy
+23,166
New +$922K ﹤0.01% 2096
2024
Q2 		– Sell
-100,656
Closed -$2.86M – 4019
2024
Q1 		$2.86M Buy
100,656
+47,312
+89% +$1.07M ﹤0.01% 1558
2023
Q4 		$709K Buy
+53,344
New +$521K ﹤0.01% 2104
2023
Q2 		– Sell
-17,726
Closed -$204K – 2538
2023
Q1 		$204K Buy
+17,726
New +$230K ﹤0.01% 1933

Other funds holding DYN

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Atlas Venture Life Science Advisors
Atlas Venture Life Science Advisors Cambridge, Massachusetts $631M AUM 38.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Qube Research & Technologies (QRT)'s DYN Position: Q3 2026 in Review

Qube Research & Technologies (QRT) opened a new position in Dyne Therapeutics (DYN) in Q3 2026: 218,805 shares worth $3.52M. The stake represents ﹤0.01% of the portfolio and ranks #2007 among its holdings. This is a return to the name: Qube Research & Technologies (QRT) previously reported a position in DYN as recently as Q1 2026.

Qube Research & Technologies (QRT) first reported a position in DYN in Q1 2023 and has held it in 11 quarters since. The position peaked at $10.5M in Q3 2025. 179 funds tracked by Wall St. Rank hold DYN as of Q3 2026.

  • Qube Research & Technologies (QRT) held 218,805 shares of Dyne Therapeutics worth $3.52M as of Q3 2026.
  • Dyne Therapeutics was a new Qube Research & Technologies (QRT) position in Q3 2026.
  • Dyne Therapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q3 2026, its #2007 holding.
  • Qube Research & Technologies (QRT) first reported a position in Dyne Therapeutics in Q1 2023 and has held it in 11 quarters since.
  • Qube Research & Technologies (QRT)'s Dyne Therapeutics position peaked at $10.5M in Q3 2025.
  • 179 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q3 2026, filed 13 Nov 2026.